It remained close to the business through a difficult period in 200809 when flutiform failed to gain us approval, and was involved in a capital raising in 2014. The company develops novel therapeutic drugs based on its technology platforms for. We are one of the few companies globally that have developed dry powder inhalers dpi, pressurised metered dose inhalers pmdi and nebulisers. Get the latest vectura stock price and detailed information including news, historical charts and realtime prices. Skyepharma share price history historical data for skp. It has products in the areas of oral and topical delivery, as well as in inhalation and injectable technologies. They also gave media headlines about the company a news buzz of 0. The company validates drug delivery technologies to develop oral and inhalation pharmaceutical products. Todays update from skyepharma was, on the face of it, rather encouraging. Entasis, gardp partner on novel antibiotic for drugresistant gonorrhea. Skyepharma plc has announced its plans to acquire depotech corp. Skyepharma plc announces regulatory application rns market newslondonmarketwire march 23, 2009 skyepharma announces filing of new drug applicationfor flutiformtm to the fda london, uk, 23. Skyepharma plc clarification of financial position biospace. Vectura group services limited free company information from companies house including registered office address, filing history, accounts, annual return, officers, charges, business activity.
In the legal profession, information is the key to success. You have to know whats happening with clients, competitors, practice areas, and industries. Skyepharma strives to deliver clinical benefits for patients by using its multiple delivery technologies to create enhanced versions of existing pharmaceutical. Investegate skyepharma plc announcements skyepharma plc. A bid by disgruntled shareholders at uk firm skyepharma to supplant nonexecutive chairman jerry karabelas has failed. The new terms deferred the earliest dates at which the bondholders may call for. Skyepharma plc develops pharmaceutical products benefiting from world leading drug delivery technologies that provide easiertouse and more effective drug formulations. It is based in chippenham and is listed on the london stock exchange. Skyepharma plc skyepharmasmission is to become one of the worlds leading speciality drug delivery companies, powered through excellence in its oral and inhalation technologies. At an extraordinary general meeting held yesterday, the rebels, centered around investment group north atlantic value, proposed bob thian as a director of the company, but were voted down. Key events include skyepharma events which occurred premerger completion 10 june 2016.
The transition date to ifrs for skyepharma plc is january 1, 2004. Why shares in skyepharma plc crashed over 15% today. Latest company news for skyepharma stock market wire. Skyepharma looks to acquire depotech pharmaceutical. Shares provides unbiased commentary, ideas, views and news on stocks, funds, pensions and savings. Skyepharma strives to deliver a clinical benefit for patients by using its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. The company was formed in 1997 as a startup pharmaceuticals business. In 2004 it was listed on the alternative investment market. Skyepharma plc, a drug delivery company, engages in the research and development, licensing, manufacture, and sale of prescription pharmaceutical products. In 2007 it acquired innovata plc, another developer of pulmonary products, and then moved on the full list of the london stock exchange.
Skp skyepharma is a drug research and development company with a leading drug deliveries technology business, specialising in. The share data supplied on this page is provided by aj bell media and incorporates share prices, market news, indices, charts, fundamentals, heatmaps, stock. Learn more about skyepharma cdmo and our current vacancies. Skp insider trading activity skyepharma marketbeat. If this is an annual report, indicate by check mark whether the registrant is a shell. There are now eleven approved products incorporating skyepharmas technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced.
Skyepharma plc 4648 grosvenor gardens london, greater london sw1 w0eb phone. Preliminary statement of annual results skyepharma plc. Vectura was advised by rothschild and jp morgan and skyepharma by lazard. Revenues shown are reported revenues and therefore only include skyepharma revenues in hy16 for the period post merger completion 10 june 2016 2. Under the terms of the deal, skyepharma shareholders will be entitled to 2.
Vectura group services limited overview free company. We are a pharmaceutical company located near lyon france with a dynamic team of 120 employees. Skyepharma is a speciality drug delivery company with a proven range of oral and inhalation technologies. Skp dividends per share explanation, calculation, historical data and more. Depodur cii, previously known as depomorphine, is a morphine sulfate extendedrelease liposome injection see depot injection, product of pacira pharmaceuticals formerly skyepharma plc. Hbmn has been an investor in skyepharma since 2001 and has taken a private equitystyle approach, owning a significant proportion of the company 28. Skyepharma current vacancies discover and apply here. Helping you bring inhaled medicines to market vectura. On 10 june 2016 vectura completed a merger with skyepharma. Director deals skyepharma plc skp peter grant, chief executive officer, bought 32 shares in the company on the 29th april 2016 at a price of 473. Stock research history is based on the obermatt method.
Skyepharma plc does not currently have any hardcopy reports on. Which company executives are buying and selling shares of skyepharma lon. The cma has today decided that the anticipated acquisition by vectura group plc of skyepharma plc does not qualify for investigation under the merger. Skp, the expert oral and inhalation drug development company, announces that its oral business has signed an exclusive feasibility, development and licence agreement with lucideon limited, part of lucideon group ltd lucideon, the international materials development and commercialisation. Skyepharma has confirmed that, at the annual general meeting held earlier today, all resolutions were passed with the requisite majorities on a show of hands. Why shares in skyepharma plc crashed over 15% today the. Get alerts on skyepharma plc when a new story is published. The name change reflects paciras transformation from a former business unit of skyepharma plc to an independent, private company with existing commercial products, a strong product in clinical development, and novel drug delivery. View the most recent insider trading activity for skp stock at marketbeat. Skyepharma stock research and rating obermatt research. In 1999 it acquired coordinated drug development and the centre for drug formulation studies. Merger with skyepharma plc completed on 10 june 2016. Financial reporting date used for calculating ranks.
474 1196 805 634 96 962 794 1431 1515 1040 60 946 1152 303 960 1143 809 1479 1492 477 1209 320 1029 780 784 660 10 1077 103 898 1470 290 677 407 740 1358